IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology

Teitelbaum, 1997, Osteoclasts, macrophages and the molecular mechanism of bone resorption, J. Leuk. Biol., 61, 381, 10.1002/jlb.61.4.381 Blair, 1998, How the osteoclast degrades bone, Bioessays, 20, 837, 10.1002/(SICI)1521-1878(199810)20:10<837::AID-BIES9>3.0.CO;2-D Greenfield, 1999, Regulation of osteoclast activity, Life Sci., 65, 1087, 10.1016/S0024-3205(99)00156-3 Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone densite, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3 Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X Khosla, 2001, Minireview: the OPG/RANKL/RANK system, Endocrinology, 142, 5050, 10.1210/en.142.12.5050 Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852 Ikeda, 2001, Determination of three isoforms of the receptor activator of nuclear factor kappaB ligand and their differential expression in bone and thymus, Endocrinology, 142, 1419, 10.1210/en.142.4.1419 Chesneau, 2003, Catalytic properties of ADAM 19, J. Biol. Chem., 278, 22331, 10.1074/jbc.M302781200 Lam, 2001, Cristal structure of the TRANCE/RANKL cytokine reveals determinants of receptor–ligand specificity, J. Clin. Invest., 108, 971, 10.1172/JCI13890 Takami, 2000, Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts, Endocrinology, 141, 4711, 10.1210/en.141.12.4711 Lee, 2003, Participation of protein kinase C β in osteoclast differentiation and function, Bone, 32, 217, 10.1016/S8756-3282(02)00976-6 Lee, 2002, Regulation of receptopr activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures, Bone, 31, 252, 10.1016/S8756-3282(02)00804-9 Komarova, 2003, RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts, J. Biol. Chem., 278, 8286, 10.1074/jbc.M206421200 Lee, 2003, Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts, Biochem. Biophys. Res. Commun., 305, 211, 10.1016/S0006-291X(03)00695-8 Hsu, 1999, Tumor nacrosis factor family member RANK mediates osteoclast differentiation and activation by osteoprotegerin ligand, Proc. Natl. Acad. Sci. U.S.A., 96, 3540, 10.1073/pnas.96.7.3540 Lomaga, 1999, TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, Genes Dev., 13, 1015, 10.1101/gad.13.8.1015 Kanazawa, 2003, TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis, J. Bone Miner. Res., 18, 443, 10.1359/jbmr.2003.18.3.443 Armstrong, 2002, A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function, J. Biol. Chem., 277, 44347, 10.1074/jbc.M202009200 Li, 2000, RANK is the intrinsic hematopoietic cell surface receptor that control osteoclastogenesis and regulation of bone mass and calcium metabolism, Proc. Natl. Acad. Sci. U.S.A., 97, 1566, 10.1073/pnas.97.4.1566 Iotsova, 1997, Osteopetrosis in mice lacking NF-κB1 and NF-κB2, Nat. Med., 3, 1285, 10.1038/nm1197-1285 Li, 2002, p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function, Endocrinology, 143, 3105, 10.1210/en.143.8.3105 Baud, 1999, Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain, Genes Dev., 13, 1297, 10.1101/gad.13.10.1297 Tan, 1997, Caracterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells, Gene, 204, 35, 10.1016/S0378-1119(97)00509-X Mizuno, 2002, Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis, J. Bone Miner. Metab., 20, 337, 10.1007/s007740200049 Hakeda, 1998, Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts, Biochem. Biophys. Res. Commun., 251, 796, 10.1006/bbrc.1998.9523 Micigami, 2001, Receptor activator of nuclear kappa B ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma, Cancer Res., 61, 1637 Lee, 2003, Differencies in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone, J. Orthop. Res., 21, 62, 10.1016/S0736-0266(02)00095-5 Jones, 2002, Role of RANKL and RANK in bone loss and arthritis, Ann. Rheum. Dis., 61, ii32, 10.1136/ard.61.suppl_2.ii32 Ritchlin, 2003, Machanism of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis, J. Clin. Invest., 111, 821, 10.1172/JCI200316069 Haynes, 2001, The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis, J. Bone Joint Surg. Br., 83, 902, 10.1302/0301-620X.83B6.10905 Sabokbar, 2003, Two distinct cellular machanisms of osteoclast formation and bone resorption in periprosthetic osteolysis, J. Orthop. Res., 21, 73, 10.1016/S0736-0266(02)00106-7 Fuller, 2002, TNFalpha potently activates osteoclasts, though a direct action independent and strongly synergistic with RANKL, Endocrinology, 143, 1108, 10.1210/en.143.3.1108 Black, 1997, A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells, Nature, 385, 729, 10.1038/385729a0 Zou, 2001, Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism, J. Cell Biochem., 83, 70, 10.1002/jcb.1202 Thomson, 1987, Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption, J Immunol., 138, 775, 10.4049/jimmunol.138.3.775 König, 1988, Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [3H]tetracycline excretion from prelabeled mice, J. Bone Miner. Res., 3, 621, 10.1002/jbmr.5650030607 Bingham, 2002, The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation, J. Rheumatol. Suppl., 65, 3 Sato, 1997, Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells, Br. J. Haematol., 97, 356, 10.1046/j.1365-2141.1997.562704.x Hsu, 1995, The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation, Cell., 81, 495, 10.1016/0092-8674(95)90070-5 Reinhard, 1997, Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2, EMBO J., 16, 1080, 10.1093/emboj/16.5.1080 Abu-Amer, 2000, Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis, J. Biol. Chem., 275, 27307, 10.1016/S0021-9258(19)61511-5 Kaji, 2001, Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6, J. Bone Miner Res., 16, 1593, 10.1359/jbmr.2001.16.9.1593 Kobayashi, 2000, Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction, J. Exp. Med., 191, 275, 10.1084/jem.191.2.275 Dinarello, 1994, The interleukin-1 family: 10 years of discovery, FASEB J., 8, 1314, 10.1096/fasebj.8.15.8001745 Jimi, 1998, Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1, J. Biol. Chem., 273, 8799, 10.1074/jbc.273.15.8799 Lorenzo, 1998, Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy, Endocrinology, 139, 3022, 10.1210/en.139.6.3022 Xing, 2003, Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption, J. Bone Miner. Res., 18, 260, 10.1359/jbmr.2003.18.2.260 Bresnihan, 1998, Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist, Arthritis Rheum., 41, 2196, 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2 Torcia, 1996, Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors, Exp. Hematol., 24, 868 Heymann, 2000, gp130 cytokine family and bone cells, Cytokine, 12, 1455, 10.1006/cyto.2000.0747 Taguchi, 1998, Interleukin-6-type cytokines stimulates mesenchymal progenitor differentiation toward the osteoblastic lineage, Proc. Assoc. Am. Phys., 110, 559 Holt, 1996, Osteoclast are not the major source of interleukin-6 in mouse parietal bone, Bone, 18, 221, 10.1016/8756-3282(95)00482-3 Kotake, 1996, Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids rheumatoid arthritis patients are responsible for osteoclast-like cell formation, J. Bone Miner. Res., 11, 88, 10.1002/jbmr.5650110113 Kuhihara, 1990, IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release, J. Immunol., 144, 4226, 10.4049/jimmunol.144.11.4226 Devlin, 1998, IL-6 mediates the effects of IL-1 or TNF, but not PTHrp or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures, J. Bone Miner. Res., 13, 393, 10.1359/jbmr.1998.13.3.393 De la Mata, 1995, Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo, J. Clin. Invest., 95, 2846, 10.1172/JCI117990 Hattersley, 1988, Human macrophage colony-stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone, J. Cell Physiol., 137, 199, 10.1002/jcp.1041370125 Udagawa, 1995, Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors, J. Exp. Med., 182, 1461, 10.1084/jem.182.5.1461 Bellido, 1996, Detection of receptors for interleukin-6, interleukin-11, leukaemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells, J. Clin. Invest., 97, 431, 10.1172/JCI118432 Palmqvist, 2002, IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB Ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvaria, J. Immunol., 169, 3353, 10.4049/jimmunol.169.6.3353 Ohsaki, 1992, Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone, Endocrinology, 131, 2229, 10.1210/en.131.5.2229 Athanasou, 1988, Immunocytochemical analysis of the human osteoclast: phenotypic relationship to other marrow-derived cells, Bone Miner., 3, 317 Linkhart, 1991, Interleukin-6 messenger mRNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: regulation by interleukin-1, J. Bone Miner. Res., 6, 1285, 10.1002/jbmr.5650061204 Ishimi, 1992, Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): regulation of its production and possible roles in bone metabolism, J. Cell Physiol., 152, 71, 10.1002/jcp.1041520110 Girasole, 1994, Interleukin-11: a new cytokine critical for osteoclast development, J. Clin. Invest., 93, 1516, 10.1172/JCI117130 Greenfield, 1993, Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemis inhibitory factor mRNA, J. Bone Miner. Res., 8, 1163, 10.1002/jbmr.5650081003 Sanders, 2000, Stern. Protein kinase C involvement in interleukin-6 production by parathyroid hormone and tumor necrosis factor-alpha in UMR-106 osteoblastic cells, J. Bone Miner. Res., 15, 885, 10.1359/jbmr.2000.15.5.885 Kondo, 2001, Signal transduction system for interleukin-6 synthesis stimulated by lipopolysaccharide in human osteoblasts, J. Interferon Cytokine Res., 21, 943, 10.1089/107999001753289550 Thabard, 2001, Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells, Biochem J., 358, 193, 10.1042/0264-6021:3580193 Ragab, 2002, Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells, Am. J. Physiol. Cell Physiol., 283, C679, 10.1152/ajpcell.00421.2001 Fujikawa, 2001, The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, 3, 6, and 11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells, Bone, 28, 261, 10.1016/S8756-3282(00)00453-1 Kudo, 2002, Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation, J. Pathol., 198, 220, 10.1002/path.1190 Azuma, 2000, Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts, J. Biol. Chem., 275, 4858, 10.1074/jbc.275.7.4858 Lam, 2000, TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand, J. Clin. Invest., 106, 1481, 10.1172/JCI11176 Komine, 2001, Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture, Bone, 28, 474, 10.1016/S8756-3282(01)00420-3 Zhang, 2001, Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways, J. Biol. Chem., 276, 563, 10.1074/jbc.M008198200 Hotokezaka, 2002, UO126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells, J. Biol. Chem., 277, 47366, 10.1074/jbc.M208284200 Kurokouchi, 1998, TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells, J. Bone Miner. Res., 13, 1290, 10.1359/jbmr.1998.13.8.1290 O’Brien, 2000, Expression levels of gp130 in bone marrow stromal cells determiune the magnitude of osteoclastic signals generated by IL-6-type cytokines, J. Cell Biochem., 14, 532, 10.1002/1097-4644(20001215)79:4<532::AID-JCB20>3.0.CO;2-U Menaa, 2000, Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone, J. Clin. Invest., 105, 1833, 10.1172/JCI9133 Neale, 2000, Osteoclast differentiation from circulating mononuclear precursors in Paget’s disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL, Bone, 27, 409, 10.1016/S8756-3282(00)00345-8 Sugiyama, 2001, Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis, J. Bone Miner. Metab., 19, 89, 10.1007/s007740170046 Kudo, 2003, Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism, Bone, 32, 1, 10.1016/S8756-3282(02)00915-8 Ishida, 2002, Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator, J. Biol. Chem., 277, 41147, 10.1074/jbc.M205063200 Cappellen, 2002, Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B, J. Biol. Chem., 277, 21971, 10.1074/jbc.M200434200 Goltzman, 2001, Osteolysis and cancer, J. Clin. Invest, 107, 1219, 10.1172/JCI13073 Zhang, 2001, Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone, J. Clin. Invest, 107, 1235, 10.1172/JCI11685 Brown, 2001, Osteoprotegerin and RANK ligand expression in prostate cancer, Urology, 57, 611, 10.1016/S0090-4295(00)01122-5 Nagai, 2000, Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation, Biochem. Biophys. Res. Commun., 269, 532, 10.1006/bbrc.2000.2314 Huang, 2002, Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases, J. Clin. Pathol., 55, 877, 10.1136/jcp.55.11.877 Thomas, 1999, Breast cancer cells interact with osteoblasts to support osteoclast formation, Endocrinology, 140, 4451, 10.1210/en.140.10.4451 Chikatsu, 2000, Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro, Biochem. Biophys. Res. Commun., 267, 632, 10.1006/bbrc.1999.2008 Good, 2002, Immunohistochemistry study of receptor activator of nuclear kappa-B ligand (RANK-L) in human osteolytic bone tumors, J. Surg. Oncol., 79, 174, 10.1002/jso.10067 Lipton, 2002, Serum osteoprotegerin levels in healthy controls and cancer patients, Clin. Cancer Res., 8, 2306 Grimaud, 2003, Receptor activator of nuclear factor (B ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, Am. J. Pathol., 163, 2021, 10.1016/S0002-9440(10)63560-2 Roux, 2002, RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone, Am. J. Clin. Pathol., 117, 210, 10.1309/BPET-F2PE-P2BD-J3P3 Alvarez, 2003, Serum osteoprotegerin and its ligand in Paget’s disease of bone: relationship to disease activity and effect of treatment with bisphosphonate, Arthritis Rheum., 43, 824, 10.1002/art.10834 Ueland, 2003, Age-related in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study, J. Clin. Endocrinol. Metab., 88, 1014, 10.1210/jc.2002-020977 Terpos, 2003, Soluble receptor activator of nuclear factor kappa B Ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index, Blood, 102, 1064, 10.1182/blood-2003-02-0380